Tessa’s CD30 CAR T-cell Therapy for Lymphoma Granted RMAT Status by FDA
News
The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Tessa Therapeutics’ investigational CD30-targeted CAR T-cell therapy for treating relapsed or refractory classical Hodgkin’s lymphoma. This ... Read more